Conversely, elevated levels of NLRP1 are linked to reduced PFS in LGG, PRAD, and STAD, while decreased expression of NLRP1 is associated with a poorer PFS prognosis in ACC, CHOL, and HNSC. Here, NLRP1 is linked to prostate adenocarcinoma.